Cannabinoid Use for Chronic Pain: Evidence and Insights from Recent Research

Chronic pain is a persistent health challenge affecting millions of people worldwide. Managing it often requires a combination of medications, lifestyle changes, and alternative therapies. Recently, cannabinoids, compounds found in the cannabis plant, have gained attention as potential options for pain management. A systematic review published in the Annals of Internal Medicine offers new insights into how short-term cannabinoid use may influence chronic pain and associated side effects.

This blog explores the findings of the study, the types of cannabinoids available, and what patients and healthcare providers should consider when evaluating these treatments.

What Are Cannabinoids?

Cannabinoids are chemical compounds that interact with the body’s endocannabinoid system, which plays a role in regulating pain, mood, appetite, and other physiological processes. The two most well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD).

• THC is the psychoactive component responsible for the "high" associated with cannabis.
• CBD is non-psychoactive and is often marketed for potential therapeutic effects, including pain relief and inflammation reduction.

Cannabinoid products vary widely in their THC-to-CBD ratios. Understanding this ratio is essential because it can influence both the effectiveness and potential side effects of a product.

The Study: Short-Term Cannabinoid Use for Chronic Pain

The review, conducted by Dr. Roger Chou and colleagues at Oregon Health & Science University, assessed evidence from 25 short-term randomized controlled trials. These trials included a total of 2,303 participants and examined treatment durations ranging from one to six months.

The researchers classified cannabinoid products by:

1. THC-to-CBD ratio: High, comparable, or low.
2. Source: Whether synthetic or plant-extracted.
3. Administration method: Oral, oromucosal (absorbed through the mouth), or other forms.

The study aimed to update the scientific evidence on the effects of cannabinoids in chronic pain management, with a focus on both benefits and adverse events.

Key Findings

Pain Reduction

• High THC-to-CBD products: Oral synthetic or purified high-THC products, such as nabilone, demonstrated a modest reduction in pain severity. Nabilone showed a pooled difference of −1.59 points in pain reduction, indicating a moderate benefit. Dronabinol, another THC-only product, did not show significant improvement.
• Comparable THC-to-CBD products: Oromucosal products with a balanced THC-to-CBD ratio also showed slight improvements in pain, with a pooled difference of −0.54 points.
• Low THC-to-CBD products: These interventions appeared to provide little or no benefit for pain management.

The overall takeaway is that while some cannabinoid products can reduce pain in the short term, the effects are generally modest.

Adverse Events

The study highlighted that cannabinoids, particularly products with higher THC content, were associated with several common adverse events, including:

• Dizziness
• Sedation or drowsiness
• Nausea

Interestingly, CBD-only products did not appear to increase the risk of these side effects, whereas mixed THC/CBD products with low THC levels still showed a small increase in adverse events.

This distinction is crucial for patients and healthcare providers to consider. While high THC products may offer modest pain relief, they also come with an increased likelihood of uncomfortable or even dangerous side effects.

Implications for Patients and Providers

Dr. Chou emphasized that many people use CBD-based products, often purchased from dispensaries, with the hope of improving pain. However, he noted that scientific evidence is limited and benefits may be modest. His research provides a foundation for making informed decisions about cannabinoid use.

Key considerations include:

1. Individual variability: Patients respond differently to cannabinoids depending on genetics, metabolism, prior experience with cannabis, and the type and severity of pain.
2. Product quality: The quality and labeling of cannabinoid products vary, especially in unregulated markets. Purity, potency, and THC-to-CBD ratios may not always match what is advertised.
3. Short-term vs. long-term effects: This review focused on short-term use. Evidence for long-term safety and effectiveness remains limited.
4. Side effect monitoring: Even if a product shows modest benefits, patients should be aware of potential side effects like dizziness, sedation, and nausea, particularly when using high THC formulations.

Understanding the Different Cannabinoid Products

Cannabinoid products can be categorized by several factors:

1. THC-Only Products: Examples include dronabinol and nabilone. These may provide pain relief but also carry higher risks for side effects and psychoactive effects.
2. CBD-Only Products: Often marketed for wellness purposes, these are generally safe but show minimal evidence for pain reduction.
3. Balanced THC/CBD Products: These have comparable levels of THC and CBD, offering some pain relief with moderate side effects.
4. Low THC-to-CBD Products: These appear least effective for pain but may still cause mild adverse events.

Patients should work closely with healthcare providers to choose the product type that aligns with their medical needs and risk tolerance.

Regulatory and Safety Considerations

The availability of cannabinoid products varies depending on regional regulations. In the United States, CBD products derived from hemp with less than 0.3% THC are legal federally, while THC-containing products may only be legal in certain states.

The lack of standardization in many over-the-counter products poses challenges for both patients and clinicians. Laboratory testing and clear labeling are critical for safe use.

What the Research Does Not Answer

While this study sheds light on short-term outcomes, several questions remain:

• Long-term safety: Chronic use of cannabinoids may have effects not captured in short-term studies, including potential dependency, cognitive changes, or interactions with other medications.
• Optimal dosing: The most effective dose for pain relief while minimizing side effects is still unclear.
• Comparative effectiveness: How cannabinoids compare to traditional pain medications, such as opioids or non-steroidal anti-inflammatory drugs, needs further investigation.
• Specific pain conditions: Evidence is limited on which types of chronic pain respond best to cannabinoids, whether neuropathic, musculoskeletal, or inflammatory pain.

Clinical Recommendations

Based on current evidence, healthcare providers may consider cannabinoids for patients with chronic pain who have not responded to conventional therapies. Some practical points include:

• Start with the lowest effective dose and titrate gradually.
• Consider THC-to-CBD ratio carefully based on desired effects and tolerance for side effects.
• Monitor for dizziness, sedation, nausea, or other adverse reactions.
• Encourage open communication about product source, quality, and dosage.
• Avoid high THC products in patients with a history of psychiatric disorders or high risk of substance misuse.

Final Thoughts

Cannabinoids are an emerging option for chronic pain management, but their use requires caution and careful consideration. High THC or balanced THC/CBD products may offer modest pain relief, but side effects such as dizziness and sedation are common. CBD-only products are generally safe but may not provide meaningful pain reduction.

This evidence emphasizes the importance of an informed approach, guided by clinical judgment and patient preferences. Patients should not self-medicate based solely on anecdotal reports or commercial claims, as product quality and dosing can vary widely.

As research continues to evolve, future studies may provide clearer guidance on optimal formulations, dosing schedules, and long-term safety. For now, cannabinoids remain a potentially useful tool in the broader toolbox of chronic pain management, particularly for patients seeking alternatives to traditional medications.

Source

• Chou R, et al. Study on short-term use of cannabinoids for chronic pain. Annals of Internal Medicine. Published Dec. 23, 2025.

Disclaimer

This article is intended for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Individual responses to medications may vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment regimen.